Grant Playter

The partnership will see Flagship and Pfizer work to create a new pipeline of innovative medicines.

The expanded deal, now potentially worth more than $1.2 billion, will work to develop in vivo therapies, including sickle cell disease.

Jeff Fischer, co-founder and president of Longhorn Vaccines and Diagnostics, discusses the history and ongoing development of both protein- and mRNA-based vaccines.

Westlake’s third fund of $450 million will be used to grow early stage biotechnology companies.

Laboratoire HRA Pharma norgestrel is the first daily tablet for nonprescription use to prevent pregnancy.

Eisai’s lecanemab-irmb was converted from an accelerated approval to a traditional approval.

Thermo Fisher Scientific’s new tumoroid culture medium kit is designed to help cancer researchers better model the disease.

Eurofins Genomics Blue Heron’s novel mRNA synthesis service is designed for customizable applications.

If we view a change opposite of one’s interest as antithetical to innovation, we risk losing sight of our ultimate goal.

Donaldson Company’s €136 million (US$148 million) acquisition of Univercells is designed to broaden its portfolio of biomanufacturing solutions.

Mason Ailstock, CEO of the Rowen Foundation, discusses incubators and their potential to promote innovation.

UCB’s rozanolixizumab-noli is approved for treatment of generalized myasthenia gravis in certain adult patient groups.

FDA approved Pfizer’s once-weekly human growth hormone analog for treatment of growth failure in pediatric patients.

The persistent poverty initiative aims to fight the cumulative effects of persistent poverty on cancer outcomes.

Sobi has officially acquired CTI, a biopharma company focused on blood related cancers and rare diseases, in a merger valued at approximately $1.7 billion.

Geert Moens, Global Platform Leader Vial Closure Systems, Datwyler Healthcare, discusses recent technologies in the film and spray coatings market.

The Segmentation by Exogenous Perfusion system uses a cell’s location in the tumor to find differences in gene activity.

FDA’s new draft guidance outlines key considerations for psychedelic drug development programs.

Sanofi’s Open Innovation Portal is designed to promote community feedback and propose novel solutions to various problems in the healthcare landscape.

Sandbox AQ’s molecular simulation division is collaborating with companies like AstraZeneca and Sanofi to develop novel treatments for various disorders.

Chris Preti, CEO of Jubilant HollisterStier Contract Manufacturing Services, shares insight into the outsourcing industry.

The new guidelines contain formulation recommendations for vaccines launching in autumn 2023.

FDA’s new voluntary pilot program is designed to help clinicians select appropriate cancer treatments for patients.

Researchers at the University of Waterloo have developed a liquid-liquid encapsulation system for use in sustainable encapsulation processes.

Eli Lilly & Company will pay Verve Therapeutics up to $525 million to advance a lipoprotein gene editing research program.

Advanco’s acquisition of Vantage Consulting Group boosts its position as a provider of independent pharmaceutical serialization solutions.

The collaboration between the Pistoia Alliance and Matador Japan will work to accelerate research and promote access to a global pharmaceutical ecosystem.

Mendus and NorthX Biologics will work to develop and commercialize Mendus’ lead asset, vididencel, an allogeneic dendritic cell vaccine.

Charles River’s off-the-shelf lentiviral vector packaging plasmids are intended for use with cell and gene therapies.

The deal, valued at more than $2 billion dollars, will see Quell Therapeutics develop various T-regulatory cell therapies for AstraZeneca.